Drugs / MWX205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07634510 | Jun → Oct 2026 expected | hyperlipidemia | Shanghai Minwei Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MWX205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634510 ↗ |
| Modality | Oligonucleotide (other) | “MWX205 small nucleic acid” NCT07634510 ↗ |
| Route | Subcutaneous | “Administration: subcutaneous injection, recommended in the abdomen.” NCT07634510 ↗ |